Danaher DHR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $1.8B-11.6% | $2.03B+13.1% | $1.8B-2.8% | $1.85B+14.8% | $1.61B-13.8% | |
| Diagnostics | $2.42B-11.1% | $2.72B+10.4% | $2.46B+6.7% | $2.31B-5.7% | $2.45B-7.1% | |
| Life Sciences | $1.74B-16.7% | $2.09B+16.4% | $1.79B+0.8% | $1.78B+5.8% | $1.68B-17.3% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $920M-39.2% | $1.51B+46.1% | $1.04B+7.2% | $966M+4.4% | $925M-35.5% | |
| Recurring revenue | $5.03B-5.5% | $5.32B+6.1% | $5.02B+0.9% | $4.97B+3.2% | $4.82B-5.7% | |
| Sales by Geography | ||||||
| High-growth markets | $1.62B-19.9% | $2.03B+15.1% | $1.76B+3.8% | $1.7B+10.4% | $1.54B-19.7% | |
| North America | $2.48B-10.1% | $2.76B+6.8% | $2.58B+5.8% | $2.44B-5.6% | $2.58B-6.9% | |
| Other developed markets | $284M-22.0% | $364M+15.2% | $316M+7.5% | $294M+5.8% | $278M-22.6% | |
| Western Europe | $1.57B-7.5% | $1.69B+21.1% | $1.4B-7.4% | $1.51B+12.1% | $1.34B-9.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
